Table 3.
Risk of Death in HCC Patients after RFA.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | p value* | HR (95%CI) | p value* | |
| Sex (male/female) | 0.795 (0.542-1.167) | 0.241 | ||
| Age (>60/≤60 years) | 2.716 (1.257-5.870) | 0.011 | 2.582 (1.092-5.141) | 0.017 |
| Performance status (1/0) | 1.738 (1.107-2.728) | 0.014 | ||
| BMI (>25/≤25 kg/m2) | 0.849 (0.553-1.304) | 0.456 | ||
| INR (>1.1/≤1.1) | 1.713 (1.126-2.607) | 0.012 | ||
| Albumin (>3.5/≤3.5 g/dL) | 0.469 (0.317-0.694) | <0.001 | 0.556 (0.360-0.857) | 0.008 |
| Total bilirubin (>1.0/≤1.0 mg/dL) | 2.050 (1.371-3.064) | <0.001 | ||
| AST (>30/≤30 IU/L) | 2.348 (1.184-4.655) | 0.015 | 2.079 (1.030-4.195) | 0.041 |
| ALT (>30/≤30 IU/L) | 1.241 (0.775-1.986) | 0.368 | ||
| Platelet counts (>15×104/≤15×104/μL) | 0.544 (0.314-0.940) | 0.029 | ||
| Creatinine (>0.8/≤0.8 mg/dL) | 1.012 (0.676-1.515) | 0.954 | ||
| Child-Pugh classification (B/A) | 2.060 (1.333-3.183) | 0.001 | ||
| MELD | 1.140 (1.065-1.221) | <0.001 | 1.111 (1.019-1.211) | 0.017 |
| Anti-HCV (+/-) | 1.898 (1.127-3.197) | 0.016 | ||
| HBsAg (+/-) | 0.237 (0.075-0.749) | 0.014 | ||
| AFP (>50/≤50 ng/mL) | 1.404 (0.903-2.183) | 0.132 | ||
| DCP (>400/≤400 mAU/mL) | 2.905 (1.174-7.187) | 0.021 | ||
| No. of nodules (2/1) | 1.488 (0.934-2.372) | 0.095 | ||
| No. of nodules (3/1) | 1.384 (0.559-3.425) | 0.482 | ||
| Size of largest tumor (mm) | 1.060 (1.022-1.100) | 0.002 | 1.059 (1.020-1.100) | 0.003 |
*p values were determined with Cox proportional hazards regression models. p<0.05 indicated a significant difference.
HCC: hepatocellular carcinoma, HR: hazard ratio, CI: confidence intervals, RFA: radiofrequency ablation, BMI: body mass index, INR: international normalized ratio, AST: aspartate aminotransferase, ALT: alanine aminotransferase, MELD: model for end-stage liver disease, Anti-HCV: antibody to hepatitis C virus, HBsAg: hepatitis B surface antigen, AFP: alpha-fetoprotein, DCP: des-gamma-carboxy prothrombin